Dudum said Hims will adjust its business model to meet patient demands, "even in a draconian scenario of compounding GLP-1s not being there." Hims predicted growth of over 15% in revenue in 2026, compared with actual growth of 59% in 2025
With regular injections, you can ensure consistent B12 levels without the hassle of remembering to take pills
Kidney and cardiovascular outcomes among patients with CKD receiving GLP-1 receptor agonists: a systematic review and meta-analysis of randomized trials
Tirzepatide (Zepbound, Mounjaro) is the most effective weight loss medication, producing 15-22% average body weight loss in clinical trialssignificantly better than all other FDA-approved options
These conversions reflect the dilutions documented in community reconstitution protocols
The study also revealed a statistically significant drop in IOP after starting GLP-1 receptor agonist treatment, especially in those with a history of glaucoma or pre-existing excessive IOP. The researchers also found that GLP-1 agonist use in the management of type 2 diabetes may have possible cardiovascular advantages
